Spotlight
Money Desk
Obituaries
Classifieds
Families First
News
Weather
Specialists
Sports
Business
Opinion
Consumer
Health
Life
Out & About
Login
Weather
7 NC counties are under alert, including Johnston County.
Program
On WRAL at 6: Hidden fees in your childâs school lunch payment ð¨ð¸ 5 On Your Side shows you how to keep more money in your pocket
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
Gold
Crude Oil
Local Stocks
WRALTechWire 30
WRALTechWire 30
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Amryt Pharma Plc ADR
(NQ:
AMYT
)
N/A
UNCHANGED
Last Price
Updated: 4:00 PM EDT, Apr 11, 2023
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Amryt Pharma Plc ADR
Chiesi Farmaceutici S.p.A. Completes Acquisition of Amryt Pharma Plc
April 12, 2023
From
Amryt Pharma plc
Via
GlobeNewswire
High Court of Justice of England and Wales Sanctions Scheme of Arrangement
April 03, 2023
From
Amryt Pharma plc
Via
GlobeNewswire
Amryt Pharma Shareholders approve acquisition of Amryt Pharma by Chiesi Farmaceutici
March 22, 2023
From
Amryt Pharma plc
Via
GlobeNewswire
AMYT Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Amryt Pharma Plc Is Fair to Shareholders
February 27, 2023
From
Halper Sadeh LLC
Via
Business Wire
AMRYT PHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Amryt Pharma Plc - AMYT
February 24, 2023
From
Kahn Swick & Foti, LLC
Via
Business Wire
AMRYT PUBLISHES SCHEME CIRCULAR AND ANNOUNCES THE SHAREHOLDER MEETINGS TO CONSIDER AND VOTE ON THE CHIESI ACQUISITION WILL BE HELD ON MARCH 22, 2023
February 16, 2023
From
Amryt Pharma plc
Via
GlobeNewswire
AMRYT PHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Amryt Pharma Plc - AMYT
January 10, 2023
From
Kahn Swick & Foti, LLC
Via
Business Wire
AMYT Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Amryt Pharma Plc Is Fair to Shareholders
January 09, 2023
From
Halper Sadeh LLC
Via
Business Wire
Chiesi Farmaceutici S.p.A. to Acquire Amryt Pharma Plc
January 08, 2023
From
Amryt Pharma plc
Via
GlobeNewswire
Amryt Announces Positive Top Line Results from Phase 3 Pediatric Trial of Lomitapide in HoFH
January 05, 2023
From
Amryt Pharma plc
Via
GlobeNewswire
COMP Adopts Positive Opinion on Orphan Designation for Mycapssa® for the Treatment of Carcinoid Syndrome Associated with Neuroendocrine Tumors
December 19, 2022
From
Amryt Pharma plc
Via
GlobeNewswire
European Commission approves Mycapssa® for the treatment of Acromegaly
December 05, 2022
From
Amryt Pharma plc
Via
GlobeNewswire
Amryt Announces New Patent for Mycapssa®
November 30, 2022
From
Amryt Pharma plc
Via
GlobeNewswire
Amryt Reports Q3 2022 Financial and Operational Results
November 03, 2022
From
Amryt Pharma plc
Via
GlobeNewswire
Amryt Supports Acromegaly Awareness Day 2022
October 31, 2022
From
Amryt Pharma plc
Via
GlobeNewswire
The British Journal of Dermatology Publishes Results from Amryt’s EASE Phase 3 Trial in Epidermolysis Bullosa
October 25, 2022
From
Amryt Pharma plc
Via
GlobeNewswire
Amryt Supports Global EB Awareness Week 2022
October 24, 2022
From
Amryt Pharma plc
Via
GlobeNewswire
Amryt to Report Q3 2022 Results on November 3, 2022
October 19, 2022
From
Amryt Pharma plc
Via
GlobeNewswire
COMP adopts positive opinion on Orphan Disease Designation for Mycapssa® for the treatment of Acromegaly
October 18, 2022
From
Amryt Pharma plc
Via
GlobeNewswire
Amryt Receives Reimbursement Approval from the Dutch Ministry of Health for Myalepta® (metreleptin)
October 17, 2022
From
Amryt Pharma plc
Via
GlobeNewswire
Amryt Pharma Plc (NASDAQ:AMYT) Shareholder Notice: Investigation Concerning Possible Wrongdoing
May 04, 2022
San Diego, CA -- (SBWIRE) -- 05/04/2022 -- An investigation was announced over potential breaches of fiduciary duties by certain officers and directors at Amryt Pharma plc.
Via
SBWire
Amryt Pharma Plc (NASDAQ:AMYT) Investor Notice: Investigation over Possible Violations of Securities Laws
March 21, 2022
San Diego, CA -- (SBWIRE) -- 03/21/2022 -- Amryt Pharma plc is under investigation over potential securities laws violations in connection with certain financial statements.
Via
SBWire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.